Sarissa Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Sarissa Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-185,183	Closed	-$291K	–	10
2024 Q3	$291K	Hold	185,183	–	–	0.07%	10
2024 Q2	$331K	Hold	185,183	–	–	0.06%	10
2024 Q1	$533K	Hold	185,183	–	–	0.09%	10
2023 Q4	$237K	Hold	185,183	–	–	0.04%	9
2023 Q3	$254K	Hold	185,183	–	–	0.03%	11
2023 Q2	$272K	Hold	185,183	–	–	0.03%	11
2023 Q1	$157K	Hold	185,183	–	–	0.02%	10
2022 Q4	$254K	Hold	185,183	–	–	0.03%	11
2022 Q3	$315K	Hold	185,183	–	–	0.04%	11
2022 Q2	$383K	Sell	185,183 -2	-0%	-$5	0.04%	11
2022 Q1	$552K	Hold	185,185	–	–	0.05%	11
2021 Q4	$583K	Hold	185,185	–	–	0.05%	11
2021 Q3	$1.28M	Hold	185,185	–	–	0.1%	10
2021 Q2	$1.51M	Hold	185,185	–	–	0.12%	11
2021 Q1	$2.89M	Hold	185,185	–	–	0.28%	11
2020 Q4	$2.5M	Hold	185,185	–	–	0.26%	10
2020 Q3	$951K	Hold	185,185	–	–	0.11%	10
2020 Q2	$1.26M	Hold	185,185	–	–	0.14%	11
2020 Q1	$853K	Hold	185,185	–	–	0.11%	10
2019 Q4	$1.65M	Hold	185,185	–	–	0.14%	11
2019 Q3	$1.33M	Hold	185,185	–	–	0.17%	10
2019 Q2	$2.31M	Buy	+185,185	New	+$2.13M	0.29%	11

Other funds holding RGLS

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sarissa Capital Management's RGLS Position: Q4 2024 in Review

Sarissa Capital Management sold out of Regulus Therapeutics (RGLS) in Q4 2024, closing a stake of 185,183 shares — an estimated $291K sold.

Sarissa Capital Management first reported a position in RGLS in Q2 2019 and held it in 22 quarters. The position peaked at $2.89M in Q1 2021. 69 funds tracked by Wall St. Rank hold RGLS as of Q4 2024.

Sarissa Capital Management reported no remaining Regulus Therapeutics position as of Q4 2024 after selling out during the quarter.
Sarissa Capital Management sold 185,183 Regulus Therapeutics shares in Q4 2024, an estimated $291K.
Sarissa Capital Management first reported a position in Regulus Therapeutics in Q2 2019 and held it in 22 quarters.
Sarissa Capital Management's Regulus Therapeutics position peaked at $2.89M in Q1 2021.
69 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2024.

Based on Sarissa Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.